A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Inclusion Criteria

• •1. Patients must have recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic documentation of the original primary tumor is required via the pathology report.
• •2. Patient must have measurable disease or detectable (non-measurable) disease:
• •Measurable disease will be defined by RECIST 1.1.
• •3. Patients must have adequate bone marrow, renal, hepatic, and neurologic functions
• •4. Patients should be free of active infection requiring parenteral antibiotics.
• •5. Any other prior therapy directed at the malignant tumor, including chemotherapy, bevacizumab or other biologic or targeted agents and immunologic agents, must be discontinued at least 21 days (three weeks) prior to registration.
• •6. Any prior radiation therapy must be discontinued at least four weeks prior to registration.
• •7. Major surgery within 28 days (four weeks) prior to registration.
• •8. Patients must have had one prior platinum-based chemotherapeutic regimen for management of primary disease.
• •9. Patients must have a GOG performance status of 0 or 1.
• •10. Patients who will be enrolled under protocol amendment # 2 must have previously received bevacizumab, either discontinued due to intolerability, or progressed after at least 2 cycles of bevacizumab